Dr. Christopher L. Amling, FACS, is the John Barry Professor and Chair of the Department of Urology at Oregon Health & Science University (OHSU) where he also serves as Director of Robotic Surgery. He received his undergraduate education from the University of Oregon and his medical degree from OHSU. He did his surgery and urology residency training at Duke University Medical Center and then completed a fellowship in urologic oncology at the Mayo Clinic. Dr. Amling served in the US Navy for 20 years, attaining the rank of Captain. Before coming to OHSU in 2009, he was Program Director and Chair of Urology at the Naval Medical Center in San Diego and then Chief of the Division of Urology at the University of Alabama at Birmingham.
Dr. Amling has a longtime interest in resident training and experience in the development and assessment of resident evaluation tools. In collaboration with the ACGME, he developed the SECR resident competency evaluation system in 2001 which was made available via the ACGME website to program directors of all specialties. He served on the Urology Residency Review Committee (RRC) for six years and has been a member of other national committees related to resident education including the ACGME Urology Milestones Project Committee and the ACGME Advisory Committee on Education Outcome Assessment. Dr. Amling was Chair of the Fellowship Committee for the Society of Urologic Oncology and also served as President of the Society of University Urologists in 2009.
Dr. Amling has been on several national AUA committees including the Education Council, Research Council and the Public Media Committee, and is the recipient of the AUA Gold Cystoscope Award in 2009. He has served on the Board of Directors for both the WSAUA and SESAUA, and currently serves as President-Elect of the WSAUA. He is a member of multiple professional organizations including the American Surgical Association (ASA), the Western Urologic Forum (WUF), the American Association of Genitourinary Surgeons (AAGUS) and the Clinical Society of Genitourinary Surgeons (CSGUS). Dr. Amling has contributed over 215 peer-reviewed publications, many of which have focused on prostate cancer risk assessment and treatment outcomes. His clinical practice focuses on the utilization of robotic and minimally invasive surgery for the treatment of genitourinary malignancies.
Dr. Bock has been practicing urology in Kansas City since completing his training at the Mayo Clinic in 1991. He has special interest and expertise in the diagnosis and treatment of benign prostatic enlargement, kidney stone disease, male and female urinary incontinence, and cancers of the urinary tract. Additionally, Dr. Bock has extensive experience in the field of endoscopic urologic surgery.
Dr. Bock is actively involved in a number of clinical studies in many areas of urology. He serves as principal investigator in the majority of these studies.
Dr. Bock is certified by the American Board of Urology and is licensed in both Missouri and Kansas. He is a member of the American Urological Association, the American Association of Clinical Urologists, Metropolitan Medical Society, the South Central Section of the American Urological Association, and the Kansas City Urological Society.
Dr. Roger R. Dmochowski is Professor at the Department of Urology and Vice Chair of the Department of Surgical Sciences at Vanderbilt University in Nashville. He is also Clinical Assistant Professor in Surgery at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. He is director of the pelvic reconstructive fellowship program at Vanderbilt. His administrative responsibilities include Executive Medical Director of Quality and Safety for Vanderbilt University Health System, Associate Chief of Staff Vanderbilt University Hospital, and Medical Director of Risk Management Vanderbilt University Medical Center.
Dr. Dmochowski received his medical degree from the University of Texas Medical Branch at Galveston. He completed an internship and residency in surgery and urology at the University of Texas Medical School at Houston and at the M.D. Anderson Hospital and Tumor Institute in Texas. In addition, Dr. Dmochowski is subspecialty fellowship trained in female urology, neurourology, urodynamics and reconstructive urology – training which was completed at Kaiser Hospital Los Angeles. He completed a Masters in Management of Health Care at Owen Graduate Business School at Vanderbilt University in 2013. He is board certified in urology and female pelvic medicine and reconstructive surgery.
Dr. Dmochowski has published more than 340 articles and book chapters, and 380 abstracts, and has given over 175 presentations at various national and international meetings. Dr. Dmochowski is on the editorial board for the World Journal of Urology, Neurourology and Urodynamics, and International Journal of Urogynecology, and he is a reviewer for the Journal of Urology, and Urology. He is a Fellow of the American College of Surgeons and a member of the American Urological Association and International Continence Society. Dr. Dmochowski has been granted the Zimskind Award from the Urodynamics Society for his accomplishment in clinical treatment for incontinence. His current research interests are outcomes of incontinence therapies with a particular emphasis on quality of life issues.
Dr Douglas Husmann is the Anson L Clark Professor of Urology and former Chair of Urology at the Mayo Clinic in Rochester MN. Dr Husmann specializes in reconstructive surgery and the transitional care of the pediatric urology patient into adulthood.
Dr. Husmann received a B.S. degree with distinction and a M.D. degree with honors from the University of Nebraska. Following graduation he entered the Public Health service as a general surgery intern and resident at the United States Public Health Service Hospital, San Francisco, California and subsequently served in the Indian Health Service in Claremore, Oklahoma. He trained in urology at University of Texas Southwestern In Dallas, Texas, in Pediatric Urology and Renal Transplantation at t he Hospital for Sick Children in Toronto, Ontario and completed an American Urologic Association (AUA) Scholarship in Endocrinology at University of Texas Southwestern in Dallas, Texas.
Dr. Husmann has served on the editorial committees of the Journal of Urology and the Journal of Pediatric Urology, as the Chair of the Pediatric Section of the AUA Core Curriculum Committee, as the secretary and president of the Society for Pediatric Urology. He has been on the Written Examination Committee for the ABU/AUA both as a member, senior consultant for pediatric urology, head of the Examination Committee for the Sub-specialty of Pediatric Urology and as the Chair for the Examination Committee for the ABU/AUA.
Dr. Husmann is an avid runner, having competed in numerous 5 and 10 K races, half marathons, and marathons (26 and counting). He is devoted to his wife, PJ, and their two children, Caleb and Jessie.
Dr. Joseph is a native of Wisconsin and has an undergraduate degree from Johns Hopkins University. He completed medical school training at the University of Wisconsin and continued with urology residency at the University of Wisconsin. He went on to fellowship training in pediatric urology at Boston Children’s Hospital/Harvard Medical School.
Dr. Joseph is currently Professor of Urology within the Department of Urology at the University of Alabama at Birmingham. He is Chief of Pediatric Urology at Children’s of Alabama and holds the Beverly P. Head endowed chair in pediatric urology. Dr. Joseph has a special interest in pediatric neurourology and is a member of the Board of Directors of the Spina Bifida Association.
Dr. Joseph is a member of several organizations including a Fellow of the American College of Surgeons, a Fellow of the American Academy of Pediatrics and a past President of the Society for Pediatric Urology. Dr. Joseph has served on the ABU/AUA Joint Examination Committee as a member, consultant and past chair. He became a Diplomate of the ABU in 1987, recertified in 1995, 2005 and added Subspecialty Certification in Pediatrics in 2008.
Christopher J. Kane, MD, is a board-certified urologist who specializes in diagnosing and treating patients with prostate, kidney, bladder and testicular cancer. He has extensive expertise in robotic prostatectomy, open and laparoscopic kidney cancer surgery, and bladder and testes cancer surgery. He also provides care for conditions including benign prostatic hyperplasia (BPH) or enlarged prostate; elevated prostate-specific antigen (PSA) levels; and the presence of blood in urine (hematuria).
Dr. Kane serves as dean of clinical affairs for UC San Diego School of Medicine and chief executive officer for UC San Diego Health Physician Group. In these dual roles, Dr. Kane collaborates with UC San Diego leadership to ensure that UC San Diego Health Physician Group achieves the highest standards of service, access, quality, safety, and patient satisfaction and is integrated to support the unique and growing needs of an expanding academic health system and its growing regional network of providers.
Dr. Kane has authored more than 320 peer-reviewed articles and book chapters with a focus on prostate cancer risk factors and outcomes, prostate cancer surgery and minimally invasive surgery for prostate and kidney cancer. He serves on the editorial boards of several major urology journals as well as the National Comprehensive Cancer Network Prostate Cancer Management Guidelines Committee. He co-chaired the National Cancer Institute’s Renal Cell Carcinoma Advisory Task Force from 2012–2016.
Prior to joining UC San Diego Health, Dr. Kane held leadership positions at UC San Francisco and the Naval Medical Center San Diego. He was awarded the Distinguished Engineering Alumni Medal by UC Davis in 2011. In 2014, he was elected to membership in the American Association of Genitourinary Surgeons. He is a retired Navy Captain and a decorated veteran of Desert Storm.
Dr. Kane completed his residency at the Naval Medical Center in Oakland, Calif. He received his medical degree from Uniformed Services University of the Health Sciences in Bethesda, Maryland. Dr. Kane is board certified in urology.
Dr. Lee is Professor and Chair of the Department of Urology at The Ohio State University Wexner Medical Center where she holds the Dorothy M. Davis Endowed Chair in Cancer Research. She is also the Vice President of the OSU Physicians and Faculty Group Practice.
She obtained her undergraduate degree from Rensselaer Polytechnic Institute and her medical training at the Albany Medical College. She completed her Urology residency at the University of Michigan and her fellowship in Urologic Oncology at the Memorial Sloan Kettering Cancer Center. She was a member of the faculty at the University of Michigan for 16 years, during which time she served as Fellowship Director in Urologic Oncology, was the Director of the Office of Continuous Professional Development within the College of Medicine, and was the inaugural holder of the Dr. Robert H. and Eva M. Moyad Research Professorship. She moved to OSU in 2016.
Her medical professional focus is dedicated to improving the care of bladder cancer patients through advocacy, education and research. She has served the Bladder Cancer Advocacy Network as the President of the Scientific Advisory Board and a current member of its Board of Directors. She is a past-member of the SUO Board of Directors and currently serves as its liaison to the AJCC. She also previously served on the Board of Directors of the American Cancer Society, Lakeshore Division, and the National Medical Association. Throughout her career, she has worked to improve the surgical outcomes for bladder cancer patients through interdisciplinary research, clinical trials, and outcome studies.
Dr. Lee is active in the education of students, residents, and practicing urologists. She has supported educational initiatives through her roles on the AUA Education Council, AUA Science and Quality Council, and the AUA Update Editorial Board. She has played a key role in the board certification of urologists in America through her service on the ABU/AUA Examination Committee, the ABU Oral Board Examination Committee, and the Oncology Knowledge Assessment Test Committee of the SUO.
Dr. Lee is originally from New York, though has lived in the Midwest for most of her adult life. She is married to William (Bill) Amato, and has two children, Jackson and Ashton.
Dr. Lemack is Professor of Urology at The University of Texas Southwestern Medical Center, and Director of the Residency Program. He has a secondary appointment in the Department of Neurology. He is Board certified in Urology and Female Pelvic Medicine and Reconstructive Surgery. After graduating from Cornell University Medical College, he completed his urologic residency at The New York Hospital – Cornell Medical Center, and then a 2-year fellowship in FPMRS/Neurourology at UT Southwestern, where he has been on the faculty since 1999. His clinical practice focuses on care for patient with voiding disorders in the setting of neurological disease, as well as women with incontinence, pelvic organ prolapse and other refractory bladder disorders. His clinical research has focused on improving incontinence care for men and women with neurological conditions such as multiple sclerosis and spinal cord injury. Much of his work has involved collaborations with the NIH/ NIDDK-sponsored Urinary Incontinence Treatment Network. He currently has authored or co-authored over 140 peer-reviewed publications and over 20 book chapters.
Dr. Lemack has served on the editorial board for the Journal of Urology and is an expert reviewer for over 10 Urology journals. He currently sits on the Editorial Board for Urology Practice. He is a Past President for the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU), and is Secretary/Treasurer, and Chairman of the Certifying Examination for the American Board of Urology. He is married, has three children and has lived in Plano Texas for over 20 years.
James McKiernan, MD, the John K. Lattimer Professor of Urology, is the chair of the Department of Urology of the College of Physicians and Surgeons and urologist-in-chief at New York-Presbyterian/Columbia. Dr. McKiernan is only the sixth physician to hold this title since the founding of the department in 1917. The Department of Urology, one of the oldest and most distinguished in the nation, consistently ranks among the top in New York and throughout the United States. New York-Presbyterian's urology program ranked No. 5 in the latest U.S. News & World Report ranking of America's best hospitals. In 2015, the department ranked No. 7 in NIH grant funding among academic Urology departments in America.
Dr. McKiernan graduated from Johns Hopkins University with a BA in biology and received his MD from Columbia University College of Physicians and Surgeons. He completed his training in urology and general surgery at New York-Presbyterian Hospital, followed by a urologic surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. McKiernan's clinical practice is focused in urologic oncology and particularly on surgical therapy in high-risk patients with bladder and kidney cancers. Dr. McKiernan evaluates and treats over 1000 patients with bladder cancer every year. His research, funded by NIH and biotechnology industry grants, focuses on developing novel therapeutics for bladder cancer treatment as well as comparative effectiveness research in urologic oncology. In the management of kidney and bladder cancer, he has special expertise in organ preservation and reconstructive surgery to maximize quality of life. Dr. McKiernan's research has been published in Cancer, Cancer Research, the Journal of Clinical Oncology, JAMA Oncology, Journal of Urology, Urologic Oncology, and Urology. He has authored and co-authored more than 220 scientific articles and book chapters on urologic cancer and related issues.
For the past 10 years, he has directed a research team at Columbia University Medical Center investigating quality outcomes and effectiveness in urologic cancer surgery. He has served as the Vice Chairman for the AJCC TNM Staging Task Force, Co-Chair of the AUA Guidelines Panel on non-muscle invasive bladder cancer, as well as on the American Board of Urology and Society of Urologic Oncology Examination Committees. In addition, Dr. McKiernan is the principal investigator of the NIH-funded clinical trials program of experimental therapeutics in bladder cancer at Columbia University/NYPH, which is investigating new agents for bladder preservation in patients whose cancer has recurred after standard therapy. In collaboration with researchers at Columbia's Herbert Irving Comprehensive Cancer Center, his team continues to develop new therapeutic strategies for managing bladder cancer.
Dr. Joel B. Nelson was nominated to be a trustee of the American Board of Urology by the American Urological Association. His term extends from February 2016 – February 2022. He is the Frederic N. Schwentker Professor and Chair of Urology at the University of Pittsburgh School of Medicine and Senior Medical Director of the University of Pittsburgh Physicians.
Dr. Nelson received his undergraduate degree in philosophy from the University of Pittsburgh and a MD degree from Northwestern University Medical School. He trained in urology at Northwestern and completed an American Foundation of Urologic Disease Fellowship at the James Buchanan Brady Urological Institute at Johns Hopkins. In 1996, he joined the Department of Urology at Johns Hopkins and was named Director of Urologic Oncology at Johns Hopkins Bayview. In 1999, Dr. Nelson was appointed Chair of the newly formed Department of Urology at the University of Pittsburgh. His clinical and academic interests are focused on prostate cancer. Administratively, he oversees the 2800-member faculty practice plan of the University of Pittsburgh Medical Center.
Dr. Nelson is a Diplomate of the American Board of Urology, certified in 1998 and recertified in 2008. He is a member of the American Urological Association, Society of Urological Oncology, Society of Basic Urological Research, and American Society of Clinical Oncologists. He is a past President of the Northeastern Section of the American Urological Association. He is a member of the American Association of Genitourinary Surgeons, the Clinical Society of American Association of Genitourinary Surgeons.
Dr. Nelson is married to Elizabeth “Liz” Nelson and they have three children: Micah, Asa and Adlai. Everyone in the family has run at least one marathon; for some, it will always be one.
Dr. Eila Skinner is the Thomas A Stamey Research Professor of Urology and Chair of the Department of Urology at Stanford University. She obtained her undergraduate degree from Stanford and her medical training from Keck USC School of Medicine. She completed a residency in Urology at LAC+USC Medical Center, and a fellowship in Urologic Oncology at the Norris Cancer Center at USC. She was on the faculty in the Department of Urology at the Keck USC School of Medicine from 1990 through 2012 where she served as residency program director for over 10 years. She was recruited to Stanford University to become Chair of the Department of Urology in 2012.
Dr. Skinner is a member of several national organizations, including the Society of Urologic Oncology, Society of University Urologists, American Association of Genitourinary Surgeons, Clinical Society of Genitourinary Surgeons, and Society of Women in Urology. She has been a member of a number of committees at the American Urology Association including the Science and Quality Council, the Core Curriculum Committee, and the Guideline Committee on non-muscle invasive bladder cancer.
Dr. Skinner’s primary clinical and research focus has been in the surgical treatment of locally advanced bladder cancer, bladder reconstruction and continent urinary diversion. She has active ongoing clinical trials in the treatment of bladder cancer and other urologic malignancies.
Dr. Skinner is married to Tom Sadler and they have three children, including their eldest who is currently a resident in urology training.
Dr. Terris received her general surgery training at Duke University and urologic surgery training at Stanford University. Her urologic oncology fellowship training, also at Stanford, focused on prostate cancer diagnosis and staging. After completion of her training, she remained at Stanford as faculty member in the Department of Urology and Chief of Urology at the Palo Alto Veterans Affairs Medical Center where she was successful in accrual funding, mentoring resident/student research, published extensively, participated in numerous clinical trials, and maintained a busy clinical practice. Dr. Terris joined the faculty at AU and the Augusta Veterans Affairs Medical Center in 2002. She was named 2003-2004 Georgia Cancer Coalition Distinguished Cancer Scholar. Dr. Terris assumed the position of Program Director for the Urology Residency Training Program in 2003, Chief of Urology and has past served as president of the Society of Urology Chairs and Program Directors and a member of the Residency Review Committee for Urology. She has been repeatedly named to Top Doctors in America and America’s Best Doctors.
After receiving his M.D. from Northwestern University, Dr. Wolf completed urology residency at UCSF and then an Endourology / Laparoscopy Fellowship with Ralph Clayman. He joined the University of Michigan in 1996, and over the ensuing 20 years he served as the Director of the Division of Endourology, the Director of the Endourology / Laparoscopy Fellowship, and the Associate Urology Department Chair for Surgical Services. In 2016, he assumed his current role as Associate Chair for Clinical Integration and Operations in the Department of Surgery and Perioperative Care at Dell Medical School of the University of Texas at Austin.
Dr. Wolf has served on the Board of Directors of the Michigan Urologic Society, the Society of Academic Urology, and the Endourological Society. He chaired the American Urological Association (AUA) Practice Guidelines Committee, and the AUA Science & Quality Council. At the University of Michigan, Dr. Wolf received the Silver Cystoscope Award for Urology Residency Teaching Excellence 3 times (1999, 2002 and 2005). He was appointed the inaugural David A. Bloom Professor of Urology in 2006. The Department of Urology awarded him the Faculty Service Award in 2011 and the Outstanding Achievement Award in 2012. He was inducted into the League of Educational Excellence of the University of Michigan Medical School in 2015, and that year he also received the inaugural Program Director’s Award from the Endourological Society. In 2010, Dr. Wolf was elected to the American Association of Genitourinary Surgeons. In 2018, he started a 6-year term as a Trustee of the American Board of Urology.
An author of over 300 peer-reviewed articles and videos, and 150 invited publications, Dr. Wolf serves or has served on the editorial boards of 11 journals. His scholarly work has been recognized by awards and/or research grants from the American Foundation for Urologic Disease, the Department of Veterans Affairs, the Endourological Society, the American Society of Transplant Surgeons, and the AUA and 2 of its sections.